- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05168254
Clinical and Multiomics Study of First-line Chemotherapy for Advanced Pancreatic Cancer
December 10, 2021 updated by: duowu zou, Ruijin Hospital
Clinical and Multiomics Study of First-line Chemotherapy for Advanced Pancreatic Cancer:a Prospective Single-center Research Trial
The early symptoms of pancreatic cancer are not obvious, and the early diagnosis rate is low.
For most patients with pancreatic cancer,palliative chemotherapy is the only choice .At present, The guidance of NCCN guidelines on the selection of chemotherapy regimens for patients with advanced pancreatic cancer is only based on the physical condition(the ECOG score), which is one of the important reasons for the poor efficacy of chemotherapy in patients with advanced pancreatic cancer.Therefore, it is urgent to group pancreatic cancer patients according to tumor molecular typing and heterogeneity of response to chemotherapy drugs accurately,so as to guide the personalized treatment of patients.
Study Overview
Status
Recruiting
Conditions
Detailed Description
Based on the limitations of existing studies and the needs of clinical patients, the investigators chose two time points: after the diagnosis of pancreatic cancer (before the first-line chemotherapy), and after chemotherapy evaluation in this study, to obtain in situ samples of pancreatic cancer tissues by EUS-FNA.The samples are detected by dynamic multi-omics study before and after treatment(including genomics, transcriptomics, proteomics, metagenomics, etc.).Combined with the drug reaction and clinical outcome of patients, a comprehensive model is established to predict the clinical outcome of patients with PDAC and the choice of chemotherapy regimens, so as to screen the pancreatic cancer patients who are most likely to benefit from different chemotherapy regimens, and lay the foundation for the development of individual chemotherapy for advanced pancreatic cancer.
Study Type
Observational
Enrollment (Anticipated)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200433
- Recruiting
- Ruijin Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with advanced pancreatic ductal adenocarcinoma
Description
Inclusion Criteria:
- Age > 18 years old, male or female;
- Locally advanced or metastatic pancreatic ductal adenocarcinoma confirmed by histopathology / cytology of the primary and / or metastatic lesions and not suitable for surgical resection, and don't receive chemotherapy;
- According to the evaluation criteria of solid tumor efficacy(RECIST 1.1), there should be at least one measurable lesion (non nodular lesion with the longest diameter of 210 mm, or nodular lesion with the shortest diameter of more than 15 mm);
- Patients voluntarily participate in this study, sign informed consent, have good compliance, and cooperate with follow-up.
Exclusion Criteria:
If any of the following criteria is met, the patient should be excluded:
- Pancreatic ductal adenocarcinoma is diagnosed without histopathology / cytology;
- The target lesion has received local non-drug therapy (including radiotherapy, physical and / or chemical ablation, etc.), and there is no imaging progression;
- If the central nervous system metastasis is known, MRI should be performed to exclude it.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Accuracy of using the model to predict the therapeutic effect of drugs
Time Frame: 1.5 years
|
The difference of progression free survival (PFS)
|
1.5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy evaluation of solid tumor
Time Frame: 1.5 years
|
disease control rate (DCR)
|
1.5 years
|
the quality of participants'life
Time Frame: 1.5 years
|
According to the European Organization for research and treatment of cancer (EORTC) quality of life core scale EORTC QLQ-C30 (V3.0 Chinese version),evaluating the quality of life (QOL)
|
1.5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 1, 2021
Primary Completion (ANTICIPATED)
July 1, 2022
Study Completion (ANTICIPATED)
July 1, 2022
Study Registration Dates
First Submitted
November 13, 2021
First Submitted That Met QC Criteria
December 10, 2021
First Posted (ACTUAL)
December 23, 2021
Study Record Updates
Last Update Posted (ACTUAL)
December 23, 2021
Last Update Submitted That Met QC Criteria
December 10, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- RuijinH20201123
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Ductal Adenocarcinoma, PDAC
-
Mayo ClinicRecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | PDAC | PDAC - Pancreatic Ductal AdenocarcinomaUnited States
-
Dana-Farber Cancer InstituteRecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreatic Neoplasm | PDAC | PDAC - Pancreatic Ductal AdenocarcinomaUnited States
-
Tianjin Medical University Cancer Institute and...Not yet recruitingPDAC - Pancreatic Ductal Adenocarcinoma
-
Sun Yat-sen UniversityRecruitingPDAC - Pancreatic Ductal AdenocarcinomaChina
-
Qilu Pharmaceutical Co., Ltd.Not yet recruitingPancreatic Ductal Adenocarcinoma (PDAC)China
-
Azienda Ospedaliera Universitaria Integrata VeronaRecruitingPDAC - Pancreatic Ductal AdenocarcinomaItaly
-
Cedars-Sinai Medical CenterRecruitingPDAC - Pancreatic Ductal AdenocarcinomaUnited States
-
Qilu Hospital of Shandong UniversityCompletedPancreatic Ductal Adenocarcinoma (PDAC)China
-
Ruijin HospitalRecruitingPancreatic Ductal Adenocarcinoma, PDACChina
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers SquibbRecruitingPancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)United States